

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**信銘生命科技集團有限公司**  
**Aceso Life Science Group Limited**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 00474)**

**INSIDE INFORMATION**  
**DISCLOSURE UNDER RULES 13.09 AND 13.19 OF**  
**THE LISTING RULES**  
**DEFAULT OF FACILITY AGREEMENTS**

This announcement is made by Aceso Life Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09 and 13.19 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

On 9 March 2018 and 28 May 2021, the Group (as borrower) has entered into two facility agreements (the “**Facility Agreements**”) with, inter alia, each of an insurance company and investment fund (as lenders) respectively for certain loan facilities. The loan facilities are secured by, inter alia, the self-owned properties of the Group at 55 Mark Lane, London EC3R 7NE, the United Kingdom. As at the date of this announcement, the aggregate outstanding principal amount under the Facility Agreements was approximately GBP79.0 million (the “**Outstanding Amount**”).

Pursuant to the Facility Agreements, the Group shall repay the Outstanding Amount in full on the maturity date of 14 April 2025. The Group has failed to repay the same on the maturity date. The Group has received a letter of reservation of rights from the agent of the insurance company lender and a demand letter from the agent of the investment fund lender both dated 15 April 2025.

The Company is currently seeking legal advice in resolving the same with a view to addressing it in an appropriate manner. In addition, the Company is also in discussion with its financial adviser and potential financiers to secure fundings to repay the Outstanding Amount. The Company will publish further announcement(s) as and when appropriate in compliance with the Listing Rules and the SFO to inform the shareholders and potential investors of the Company of any material development of the same.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Aceso Life Science Group Limited**  
**Zhiliang Ou**  
*Executive Director*

Hong Kong, 16 April 2025

*As at the date of this announcement, the Board comprises two executive directors, namely Mr. Fok Chi Tak and Dr. Zhiliang Ou, J. P. (Australia); one non-executive director, namely Ms. Jiang Yang; and three independent non-executive directors, namely Mr. Mak Yiu Tong, Mr. Lam Kwan Sing and Mr. Chan Ming Sun Jonathan.*